<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="blockers upregulates ACE 2 receptor and increases the susceptibility to" exact="infection" post="lacks evidence. It is advised that patients continue the"/>
 <result pre="5% are critically ill. The most common manifestations of the" exact="infection" post="include fever (92.8%), cough (69.8%), difficulty in breathing (34.5%),"/>
 <result pre="by the virus. The altered sensorium that occurs in the" exact="infection" post="may due to hypoxia, metabolic derangements or multi-organ dysfunction."/>
 <result pre="manifestations of SARS CoV-2 Laboratory findings of SARS- CoV- 2" exact="infection" post="include normal total blood count with lymphopenia which is"/>
 <result pre="or plasma (sensitivity: 85.6%, specificity: 91%)[21] and can serve as" exact="screening" post="test for triage and epidemiological purposes [Figure 4]. Imaging"/>
 <result pre="renal replacement therapy in acute kidney injury and other supportive" exact="treatment" post="modalities are utilized in critically ill patients. The usage"/>
 <result pre="the pandemic. Immunomodulators that do not increase the risk of" exact="infection" post="include glatiramer acetate, interferons and natalizumab. Immunomodulators that increase"/>
 <result pre="acetate, interferons and natalizumab. Immunomodulators that increase the risk of" exact="infection" post="include dimethyl fumarate, fingolimod, siponimod and teriflunomide. Immunosuppressants increasing"/>
 <result pre="fumarate, fingolimod, siponimod and teriflunomide. Immunosuppressants increasing the risk of" exact="infection" post="include alemtuzumab, ocrelizumab, rituximab, mitoxantrone and cladribine.[29] With the"/>
 <result pre="isolate infected patients. This has necessitated an unprecedented method of" exact="social distancing," post="a form of target population isolation with nearly one"/>
 <result pre="unprecedented method of social distancing, a form of target population" exact="isolation" post="with nearly one third of humanity under lockdown at"/>
 <result pre="intensive care systems around the world. Containment strategies such as" exact="social distancing" post="have been attempted to flatten the curve so as"/>
 <result pre="for healthcare systems to cope with the patient load. Aggressive" exact="contact tracing" post="and isolation in the earlier local transmission stage of"/>
 <result pre="healthcare systems to cope with the patient load. Aggressive contact" exact="tracing" post="and isolation in the earlier local transmission stage of"/>
 <result pre="to cope with the patient load. Aggressive contact tracing and" exact="isolation" post="in the earlier local transmission stage of the disease"/>
 <result pre="outbreaks and resumption of economic activities within the ambit of" exact="social distancing." post="The pandemic shall entail medium to long term behavioural"/>
 <result pre="the challengesInt J Antimicrob Agents202055105924doi:10.1016/j.ijantimicag 2020.10592432081636 4CascellaMRajnikMCuomoADulebohnSCDiNapoli RFeatures, evaluation and" exact="treatment" post="coronavirus (COVID-19)InStatPearls [Internet]202038StatPearls Publishing 5HeymannDLShindoNCOVID-19:What is next for public"/>
 <result pre="proposed neurotropic mechanismsACS Chem Neurosci202011995832167747 15WuYXuXChenZDuanJHashimotoKYangLet al.Nervous system involvement after" exact="infection" post="with COVID-19 and other coronavirusesBrain Behav Immun2020doi:10.1016/j.bbi.2020.03.031 16WangHYLiXLYanZRSunXPHanJZhangBWPotential neurological"/>
 <result pre="Drug Information, Clinical Solutions2020Elsevier 27GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19:results of an open-label non-randomized clinical trialInt J"/>
</results>
